{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"}]}],"title":"ADA Positive: Overall Incidence"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"NAb Positive: Overall Incidence"}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"37"}],"units":"Participants"}],"description":"A participant was ADA (or NAb) positive if: (1) baseline titer was missing or negative and participants had \\>1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \\> 4-fold dilution increase in titer from baseline in \\> 1 post-treatment sample (treatment-boosted).","groups":[{"description":"Participants with a broader variety of hematologic malignancies and selected solid tumors, received a 0.2 mg/kg/week TTI-621 infusion until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG000","title":"Part 2: Ontorpacept (PF-07901800/TTI-621) Monotherapy"},{"description":"Participants with cHL received 0.1 mg/kg/week TTI-621 infusion along with 3 mg/kg nivolumab given every 2 weeks or a fixed dose per current FDA approved package insert for cHL.If required dose of TTI-621 could be increased up to 0.5 mg/kg/week. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.","id":"OG001","title":"Part 2: Ontorpacept (PF-07901800/TTI-621)+ Nivolumab Combination"},{"description":"Participants with CD20-positive malignancies received 0.1 mg/kg/week TTI-621 infusion along with 375 mg/m\\^2 rituximab given weekly (1 cycle) for up to 8 cycles according to the institutional standard of care. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.","id":"OG002","title":"Part 2: Ontorpacept (PF-07901800/TTI-621) + Rituximab Combination"},{"description":"Participants with CTCL and PTCL, received a 0.2 mg/kg/week TTI-621 infusion. Initial 2 weeks of 0.2 mg/kg treatment followed by intraparticipant dose intensification at an increment of 0.1 mg/kg per week up to 0.5 mg/kg within 5-8 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG003","title":"Part 3: Ontorpacept (PF-07901800/TTI-621) Monotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Immunogenicity analysis population included all treated participants with at least one ADA sample (pre-dose or post-treatment) analyzed. Here, \"Number of Participants Analyzed\" signifies number of participants who were ADA or NAb evaluable.","reportingStatus":"POSTED","timeFrame":"Part 2 and 3: From pre-infusion on day 1 up to end of study treatment (maximum treatment exposure for Part 2 was 1793 days and for Part 3 was 938 days)","title":"Part 2 and 3: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibodies (NAb)","type":"SECONDARY","unitOfMeasure":"Participants"}